Inclusion Criteria:

1. Patients must have a diagnosis of histologically confirmed ovarian cancer that has progressed or recurred in the abdomen or pelvis after salvage chemotherapy as documented by either radiologic studies or rising CA125 levels.
2. Patients must have large volume ascites- confirmed by radiologic studies.
3. There is no limit on prior courses of chemotherapy.
4. Patients must have unidimensional measurable disease or elevated CA125 and large volume ascites.

5Age >18 years.

6ECOG performance status <2 (Karnofsky >60%, see Appendix A).

7Life expectancy of greater than 12 weeks.

8Patients must have adequate organ and marrow function

9Ability to understand and the willingness to sign a written informed consent document. All patients must be informed of the investigational nature of this study and must sign an informed consent in accordance with institutional and federal guidelines.

10Timing guideline for pre-study labs and measurements:

All pre-study labs required for determination of eligibility are to be completed within 28 days of treatment Day 1.

X-rays and/or scans used for tumor measurement to determine disease status are to be completed within 28 days of treatment Day 1.

Exclusion Criteria:

1. Patients with known immunosuppressive diseases are excluded from this trial due to the known immunosuppressive nature of Alemtuzumab therapy.
2. Patients may not be receiving any other agents (investigational or otherwise) with therapeutic intent.
3. Patients with prior malignancy, except for adequately treated basal cell (or squamous cell) skin cancer, in situ cervical cancer or other cancer for which the patient has been disease free for 2 years.
4. Patients with metastases outside the abdominal cavity are excluded from this clinical trial.
5. Patients with a history of allergic reactions to Alemtuzumab or other humanized immunotherapeutics.
6. Patients with unresolved bacterial, fungal, or viral infections requiring active treatment. Patients may be registered two weeks after the conclusion of antibiotic or anti-viral therapy.

7. Patients with history of active CMV disease as Alemtuzumab therapy has been associated with CMV reactivation.

   -